|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,861,757: Crizotinib and its Patent Landscape
U.S. Patent 9,861,757, titled "Crizotinib and its Use in Treating Cancer," describes a pharmaceutical compound and its therapeutic applications, primarily focusing on anaplastic lymphoma kinase (ALK) inhibitors. The patent claims cover the chemical structure of crizotinib, pharmaceutical compositions containing it, and methods of treating certain cancers, particularly non-small cell lung cancer (NSCLC) harboring ALK rearrangements. The patent landscape indicates a competitive environment with multiple companies holding patents related to crizotinib, its analogs, and related therapeutic uses.
What is the core invention of U.S. Patent 9,861,757?
The patent's core invention is the compound crizotinib, identified by its chemical name, 3-[(1-{[2-(2,6-dichloro-3-fluorophenyl)acetyl]amino}-2-methylpropan-2-yl)amino]-2-oxo-1,2-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile. It also encompasses pharmaceutical compositions containing crizotinib and methods for treating ALK-positive cancers. This includes a specific focus on its efficacy in patients with NSCLC who exhibit a genetic alteration in the ALK gene.
What are the key claims of U.S. Patent 9,861,757?
U.S. Patent 9,861,757 contains several independent and dependent claims detailing the scope of the invention.
- Claim 1: A compound having the structure of crizotinib or a pharmaceutically acceptable salt thereof. This claim establishes the foundational chemical entity.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier. This claim covers the formulation and delivery of the active pharmaceutical ingredient.
- Claim 3: A method of treating cancer in a subject, comprising administering to the subject an effective amount of the compound of claim 1. This is a broad claim for therapeutic use.
- Claim 4: The method of claim 3, wherein the cancer is non-small cell lung cancer. This narrows the application to a specific cancer type.
- Claim 5: The method of claim 4, wherein the non-small cell lung cancer is ALK-positive. This identifies a critical patient population for efficacy.
- Claim 6: The method of claim 5, wherein the ALK-positive non-small cell lung cancer has an ALK rearrangement. This specifies the genetic basis for treatment.
- Dependent Claims (e.g., Claims 7-10): These claims may further define specific salts, carriers, dosage regimens, or combinations with other therapeutic agents, providing further specificity and protection for various aspects of crizotinib's use.
What is the asserted therapeutic indication for crizotinib under this patent?
The primary asserted therapeutic indication for crizotinib under U.S. Patent 9,861,757 is the treatment of ALK-positive non-small cell lung cancer (NSCLC). This includes patients whose tumors harbor specific genetic alterations, such as ALK rearrangements, which drive tumor growth. The patent implies a targeted therapy approach, recognizing that the efficacy of crizotinib is linked to specific biomarkers within the cancer cells.
What is the mechanism of action of crizotinib?
Crizotinib is a small-molecule tyrosine kinase inhibitor (TKI). Its mechanism of action involves inhibiting the activity of several receptor tyrosine kinases, most notably anaplastic lymphoma kinase (ALK), as well as ROS1 and MET. In ALK-positive NSCLC, the ALK gene undergoes rearrangements, leading to the expression of an aberrant fusion protein that is constitutively active and drives tumor cell proliferation and survival. Crizotinib binds to the ATP-binding pocket of ALK, preventing its phosphorylation and downstream signaling, thereby inhibiting tumor growth.
What is the current status and duration of U.S. Patent 9,861,757?
U.S. Patent 9,861,757 was granted on January 9, 2018. As a utility patent, its term is generally 20 years from the filing date of the earliest U.S. non-provisional application. Given a typical filing date for such a compound and its therapeutic use, the patent's term would have likely commenced in the mid-to-late 2000s. Therefore, the patent's expiration date would likely fall in the mid-to-late 2020s, assuming no extensions or post-grant challenges significantly alter its term. Specific information regarding patent term adjustments (PTA) or extensions (PTE) would be necessary for precise expiration dates.
Who are the key assignees or owners related to U.S. Patent 9,861,757 and its technology?
The primary assignee for U.S. Patent 9,861,757 is Pfizer Inc., a global biopharmaceutical company that developed and markets crizotinib under the brand name Xalkori. Pfizer holds a significant portfolio of patents related to crizotinib, including its synthesis, formulations, and various therapeutic uses.
What is the competitive patent landscape surrounding crizotinib?
The patent landscape for crizotinib is complex and involves multiple entities, reflecting the significant commercial interest and scientific development in this area of targeted oncology. Key aspects include:
- Pfizer's Dominance: Pfizer holds the foundational patents for crizotinib and its primary indications. These patents are critical for their market exclusivity.
- Follow-on Patents: Pfizer has secured numerous follow-on patents covering improved synthesis routes, new formulations (e.g., extended-release), combination therapies, and expanded indications for crizotinib.
- Competitor Patents: Other pharmaceutical companies have patented related ALK inhibitors, investigational compounds, and alternative treatment strategies for ALK-positive NSCLC. These can include next-generation inhibitors designed to overcome resistance to crizotinib or compounds targeting other oncogenic drivers.
- Biosimilar/Generic Competition: As foundational patents approach expiration, companies specializing in generic drug development will seek to develop and launch biosimilar or generic versions of crizotinib. This often involves navigating existing patents on manufacturing processes, formulations, and specific polymorphs.
- Intellectual Property Litigation: The highly competitive nature of oncology drug development frequently leads to patent litigation. Disputes can arise over patent validity, inventorship, infringement, and inventiveness. Pfizer has been involved in defending its crizotinib patents against challenges.
What are the implications of U.S. Patent 9,861,757 for generic drug manufacturers?
For generic drug manufacturers, U.S. Patent 9,861,757 represents a significant hurdle to market entry for crizotinib. The claims cover the compound itself, its pharmaceutical compositions, and its use in treating ALK-positive NSCLC.
- Compound Claims: Generic manufacturers must wait for the expiration of the core compound patent to legally produce and sell a generic version of crizotinib.
- Composition Claims: Even after the compound patent expires, patents covering specific pharmaceutical formulations (e.g., tablets with particular excipients, controlled-release mechanisms) can still provide market exclusivity. Generic manufacturers may need to develop alternative formulations that do not infringe these patents.
- Method of Use Claims: Method of use patents, like those in Patent 9,861,757 for treating ALK-positive NSCLC, can also impact generic entry. Generic manufacturers typically cannot market their product for an indication covered by a valid method of use patent until that patent expires or is invalidated. However, they can often market their product for "off-label" uses or for indications where no patent protection exists. The Hatch-Waxman Act provides pathways for generic companies to challenge method of use patents.
- Patent Litigation: Generic manufacturers often engage in "Paragraph IV" certifications under the Hatch-Waxman Act, asserting that their proposed generic product does not infringe the listed patents or that the patents are invalid. This often triggers patent litigation, which can delay or prevent generic entry.
How does U.S. Patent 9,861,757 compare to patents for other ALK inhibitors?
U.S. Patent 9,861,757 is representative of early patents for first-generation targeted cancer therapies. Patents for other ALK inhibitors, particularly second-generation and third-generation drugs like alectinib, brigatinib, and lorlatinib, will have different claim scopes and expiration dates.
- First-Generation (e.g., Crizotinib): Patents typically focus on the core compound, its basic compositions, and its efficacy against the primary oncogenic driver (e.g., ALK fusions). These patents often have earlier filing and expiration dates.
- Second-Generation Inhibitors: Patents for these drugs (e.g., alectinib, brigatinib) will cover their specific chemical structures, which are often designed to be more potent, selective, or to overcome resistance mechanisms that emerge with first-generation inhibitors. Their patent terms will extend later than crizotinib's foundational patents.
- Third-Generation Inhibitors: Patents for drugs like lorlatinib will focus on compounds designed to overcome resistance to both first- and second-generation inhibitors, including mutations in the ALK kinase domain. These patents will have the latest expiration dates in the ALK inhibitor class.
The comparison highlights a typical drug development lifecycle where initial broad patents are followed by patents for improved generations of drugs with later protection.
What are the potential future challenges or opportunities related to this patent?
Challenges:
- Patent Expiration and Generic Competition: As the patent term for U.S. Patent 9,861,757 and related foundational patents expires, generic versions of crizotinib will become available, potentially leading to significant price reductions and market share erosion for the originator product.
- Technological Advancements: The development of newer, more effective ALK inhibitors or alternative treatment modalities (e.g., immunotherapies, combination regimens) could reduce the clinical utility and market demand for crizotinib, irrespective of patent status.
- Resistance Mutations: The emergence of resistance mutations to crizotinib in ALK-positive NSCLC necessitates the development and patenting of next-generation inhibitors, shifting focus away from the original patent's claims.
Opportunities:
- Life Cycle Management: Pfizer may have pursued and obtained patents for new formulations, combination therapies, or expanded indications that could extend market exclusivity beyond the original patent term.
- Data Exclusivity: Regulatory data exclusivity periods, separate from patent protection, can also provide a period of market protection for the innovator drug, even after patent expiration.
- Licensing and Partnerships: For generic manufacturers, understanding the patent landscape allows for strategic planning regarding market entry, potential licensing agreements for specific patents or technologies, and the development of non-infringing processes or formulations.
- Research into Novel Applications: While the primary focus is NSCLC, continued research might uncover new therapeutic applications for crizotinib or its analogs in other ALK-driven cancers, potentially leading to new patentable inventions.
Summary of Key Patent Assertions and Exclusivity Period
U.S. Patent 9,861,757 protects the compound crizotinib and its use in treating ALK-positive NSCLC. Assigned to Pfizer Inc., it represents a foundational patent for this targeted therapy. The patent's term is projected to expire in the mid-to-late 2020s, after which generic competition is expected. The competitive landscape includes other ALK inhibitors with later patent protection, highlighting a progression in targeted therapy development. For generic manufacturers, this patent necessitates careful consideration of claim scope, formulation patents, and method of use claims, often leading to patent litigation. Future opportunities and challenges revolve around patent expiration, the emergence of new therapies, and strategies for life cycle management.
Key Takeaways
- U.S. Patent 9,861,757 covers crizotinib, its pharmaceutical compositions, and its method of treating ALK-positive non-small cell lung cancer (NSCLC).
- The patent is assigned to Pfizer Inc. and is anticipated to expire in the mid-to-late 2020s, marking a critical period for generic market entry.
- The patent landscape for crizotinib is competitive, with Pfizer holding foundational patents and other companies developing next-generation ALK inhibitors.
- Generic manufacturers must navigate core compound, composition, and method of use claims, often engaging in patent litigation to challenge exclusivity.
- The development of superior ALK inhibitors and the emergence of resistance mechanisms are key factors influencing crizotinib's long-term market position beyond patent expiry.
FAQs
1. When did U.S. Patent 9,861,757 officially grant, and what is its projected expiration date?
U.S. Patent 9,861,757 was granted on January 9, 2018. Its projected expiration date is in the mid-to-late 2020s, typically 20 years from the earliest U.S. non-provisional filing date, barring any patent term adjustments or extensions.
2. Can generic versions of crizotinib be manufactured and sold before the expiration of U.S. Patent 9,861,757?
No, generic manufacturers generally cannot legally manufacture and sell a generic version of crizotinib that infringes the claims of U.S. Patent 9,861,757 until its expiration, or unless the patent is successfully challenged and invalidated.
3. What is the significance of the "ALK-positive" designation in the patent claims?
The "ALK-positive" designation is crucial as it defines the specific patient population for whom crizotinib has demonstrated efficacy, based on the presence of ALK gene rearrangements. This allows for targeted therapy and is a key element of the patent's asserted therapeutic use.
4. Does U.S. Patent 9,861,757 cover all forms of crizotinib, or only specific formulations?
The patent covers the compound crizotinib itself, as well as pharmaceutical compositions containing it. This means it protects the active ingredient and various formulations, although specific formulations might have additional, separate patent protection.
5. How does the patent protection for crizotinib compare to that of newer ALK inhibitors like alectinib or brigatinib?
Patents for crizotinib, a first-generation ALK inhibitor, are older and have earlier expiration dates. Patents for newer ALK inhibitors like alectinib and brigatinib cover chemically distinct molecules designed to overcome resistance or improve efficacy, and therefore, they have later expiration dates, extending their respective market exclusivity periods.
Citations
[1] United States Patent 9,861,757 B2. (2018). Crizotinib and its use in treating cancer. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
